Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $1.28 Million - $2.25 Million
-15,400 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $1.03 Million - $1.33 Million
9,331 Added 153.75%
15,400 $1.83 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $605,261 - $901,125
6,069 New
6,069 $836,000
Q2 2019

Aug 14, 2019

SELL
$39.79 - $67.01 $297,589 - $501,167
-7,479 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$34.52 - $53.29 $258,175 - $398,555
7,479 New
7,479 $385,000
Q1 2018

May 15, 2018

SELL
$22.49 - $34.56 $231,646 - $355,968
-10,300 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$20.44 - $35.56 $210,532 - $366,268
10,300
10,300 $278,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Endurant Capital Management LP Portfolio

Follow Endurant Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.